Comparative Pharmacology
Head-to-head clinical analysis: ANKTIVA versus GLATIRAMER ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANKTIVA versus GLATIRAMER ACETATE.
ANKTIVA vs GLATIRAMER ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ANKTIVA is a live attenuated, nonpathogenic recombinant strain of Vibrio cholerae O1 (CVD 103-HgR) that colonizes the intestinal mucosa and elicits protective mucosal and systemic immune responses against V. cholerae, including production of vibriocidal and antitoxin antibodies.
Glatiramer acetate is a mixture of synthetic polypeptides composed of four amino acids (L-glutamic acid, L-lysine, L-alanine, and L-tyrosine). Its mechanism is not fully understood but is thought to modulate the immune system by inducing antigen-specific suppressor T cells, shifting the cytokine profile from pro-inflammatory (Th1) to anti-inflammatory (Th2), and promoting neuroprotection through increased brain-derived neurotrophic factor (BDNF) production.
Intravesical instillation of 300 mg (25 mL) once weekly for 6 weeks, followed by maintenance therapy of 300 mg once monthly for 6 or 12 months.
20 mg subcutaneously once daily for relapsing forms of multiple sclerosis.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; clinically, steady-state reached after 2-3 days
Terminal half-life is approximately 1-2 hours for the parent compound; however, clinical effects persist for days to weeks due to immunological mechanisms (e.g., antigen-specific T-cell modulation).
Renal: ~70% unchanged; fecal: ~30% as metabolites
Primarily renal excretion of intact glatiramer acetate and its metabolites; minimal biliary/fecal elimination. Exact percentages not established due to extensive metabolism.
Category C
Category A/B
Immunomodulator
Immunomodulator